Carboplatin and Paclitaxel or Oxaliplatin and Capecitabine, With or Without Bevacizumab, as First-Line Therapy in Treating Patients With Newly Diagnosed Stage II, Stage III, Stage IV, or Recurrent Stage I Epithelial Ovarian Cancer or Fallopian Tube Cancer

Conditions:   Ovarian Mucinous Cystadenocarcinoma;   Ovarian Mucinous Cystadenoma With Proliferating Activity;   Recurrent Fallopian Tube Cancer;   Recurrent Ovarian Epithelial Cancer;   Stage IA Fallopian Tube Cancer;   Stage IA Ovarian Epithelial Cancer;   Stage IB Fallopian Tube Cancer;   Stage IB Ovarian Epithelial Cancer;   Stage IC Fallopian Tube Cancer;   Stage IC Ovarian Epithelial Cancer;   Stage IIA Fallopian Tube Cancer;   Stage IIA Ovarian Epithelial Cancer;   Stage IIB Fallopian Tube Cancer;   Stage IIB Ovarian Epithelial Cancer;   Stage IIC Fallopian Tube Cancer;   Stage IIC Ovarian Epithelial Cancer;   Stage IIIA Fallopian Tube Cancer;   Stage IIIA Ovarian Epithelial Cancer;   Stage IIIB Fallopian Tube Cancer;   Stage IIIB Ovarian Epithelial Cancer;   Stage IIIC Fallopian Tube Cancer;   Stage IIIC Ovarian Epithelial Cancer;   Stage IV Fallopian Tube Cancer;   Stage IV Ovarian Epithelial CancerInterventions:   Other: quality-of-life assessment;   Drug: carboplatin;   Drug: paclitaxel;   Drug: oxaliplatin;   Drug: capecitabine;   Biological: bevacizumabSponsor:   National Cancer Institute (NCI)Suspended - verified June 2014
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials